2nd Generation SARS-CoV-2 Vaccines for Developing Countries We are developing a second generation vaccine against SARS-CoV-2, tailored to address the new variants of concern in developing countries Although vaccination campaigns are being rolled out effectively in the developed world, the situation of high infection rates and low vaccination in developing countries is triggering the emergence of multiple new SARS-CoV-2 variants of concern (VOCs) in developing countries. Of particular concern is the increasing prevalence of the P.1 and B.1.351 lineages in Latin America and Africa. This fact not only conditions a scenario of high epidemiological danger for developing countries, but also for the rest of the world, to the extent that these variants cross borders and enter new territories globally. Vaxinz Inc. is a Biotechnology company focused on vaccines against SARS-CoV-2. We have developed a 2nd generation SARS-CoV-2 vaccine platform aimed at achieving broad protection against the VOCs most prevalent in Latin America, Africa and the Caribbean. Our vaccine candidates aim to elicit a broad and potent protection against VOCs. Our Platform is based on a replication deficient human adenoviral vector, engineered to increase immunogenicity, seeking to achieve: • A single shot vaccine • Long lasting immune protection of at least 1 year • Lower dose to diminish side effects and avoid immune response against the vaccine vector Our technology is based on an established and proven vaccine platform to facilitate a rapid development, and a significant manufacturing scale up potential. Most importantly, our platform aims to respond to the urgent need of regional R&D and production of vaccines in Latin America and Sub-Saharan Africa, targeting current and future outbreaks and allowing access to vulnerable populations in Latin America and Africa.